Direct Correlation of Soluble HLA and HLA-Containing Exosomes and Inverse Correlation of Tolerance Marker-Containing Exosomes With Antibody-Mediated Rejection After Simultaneous Liver-Kidney Transplantation: A Case Study.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 16 08 2022
accepted: 16 10 2022
pubmed: 15 11 2022
medline: 21 12 2022
entrez: 14 11 2022
Statut: ppublish

Résumé

There is a lower incidence of antibody-mediated rejection (AMR) after simultaneous liver-kidney transplantation (SLKT) than after kidney-only transplantation. It has been suggested that soluble human leukocyte antigen (sHLA) produced by the liver protects the kidney from AMR. However, this hypothesis has not been tested after SLKT. We present a case of SLKT with 2 donor-specific antibodies (DSAs) (DR53, 12,364 mean fluorescence intensity [MFI]; DQ7, 1253 MFI) that displayed a decrease by day 7 (DR53, 2747 MFI; DQ7, 107 MFI). On day 351, the patient was diagnosed with kidney AMR associated with high levels of DSA (DR53, 18,542 MFI; DQ7, 22,007 MFI) that persisted until day 531. High levels of sHLA-DR/DQ and HLA-DR/DQ-containing exosomes were also detected on day 398. Consequently, the patient underwent treatment with plasmapheresis, intravenous immunoglobulin, prednisone, and rituximab. On day 752, biopsy results were negative for AMR. Moderate levels of DSA (DR53, 9798 MFI; DQ7, 1271 MFI), and baseline levels of sHLA-DR/DQ and HLA-DR/DQ-containing exosomes were observed. Increases in CD4

Identifiants

pubmed: 36376103
pii: S0041-1345(22)00697-2
doi: 10.1016/j.transproceed.2022.10.025
pii:
doi:

Substances chimiques

Isoantibodies 0
HLA Antigens 0
HLA-DR Antigens 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

2765-2768

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

Auteurs

Hay Me Me (HM)

Department of Medicine, Mayo Clinic, Phoenix, Arizona.

Ranjithkumar Ravichandran (R)

Norton Thoracic Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona.

Hasan A Khamash (HA)

Department of Medicine, Mayo Clinic, Phoenix, Arizona.

Sumi S Nair (SS)

Department of Medicine, Mayo Clinic, Phoenix, Arizona.

Katrin Hacke (K)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, Arizona.

Daniel S Ramon (DS)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, Arizona.

T Mohanakumar (T)

Norton Thoracic Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona.

Raymond L Heilman (RL)

Department of Medicine, Mayo Clinic, Phoenix, Arizona.

Andrés Jaramillo (A)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, Arizona. Electronic address: Jaramillo.Andres@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH